Effects of WBV Associated With IMT on Inflammatory Markers, Body Composition, Muscle Strength and Thickness

September 24, 2019 updated by: Helga Cecília Muniz de Souza, Universidade Federal de Pernambuco

Effects of Whole Body Vibration Associated With the Inspiratory Muscle Training Program on Inflammatory Markers, Body Composition, Muscle Strength and Thickness

Aging generates immune, muscular and functional changes. In the pre-frail elderly these changes may be increased and, therefore, preventive interventions are indicated to minimize the consequences of sarcopenia in this population. This study aims to evaluate the effects of a whole body vibration training associated with the training of inspiratory muscles on the inflammatory, muscular and body composition outcomes in pre-frail elderly women.

Study Overview

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pernambuco
      • Recife, Pernambuco, Brazil
        • Federal University of Pernambuco

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Elderly individuals able to walk without assistance
  • Good understanding to carry out the proposed tests, evaluated through the Mini Mental State Examination (MMSE).

Exclusion Criteria:

  • Contraindication or difficulty to perform evaluation procedures
  • Users of medications that interfere with the cardiovascular and / or muscular system
  • Smokers
  • Neuromuscular or degenerative diseases
  • Pulmonary comorbidities
  • Heart diseases
  • Labyrinthitis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: WBV + IMT
Whole body vibration training associated with respiratory muscle training (WBV + IMT)
The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
Active Comparator: WBV + IMTsham
Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
Sham Comparator: WBVsham + IMTsham
Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Respiratory Muscle Strength and Resistance
Time Frame: Change from Baseline respiratory muscle strength and resistance at 3 months
Maximum Inspiratory and Expiratory Pressure will be evaluated through manovacuometer
Change from Baseline respiratory muscle strength and resistance at 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Thickness of the quadriceps muscle
Time Frame: Change from Baseline thickness of the quadriceps muscle at 3 months
Ultrasound will be used to assess the thickness of the quadriceps muscle according to the pre-established protocol.
Change from Baseline thickness of the quadriceps muscle at 3 months
Diaphragmatic thickness
Time Frame: Change from Baseline diaphragmatic thickness at 3 months
Ultrasound will to use to evaluate diaphragm thickness non-invasively in the zone of apposition during tidal breathing and with changes in lung volume.
Change from Baseline diaphragmatic thickness at 3 months
Diaphragmatic mobility
Time Frame: Change from Baseline diaphragmatic mobility at 3 months
During respiration to total lung capacity, measurement of the diaphragmatic excursion will be assessed by ultrasonography.
Change from Baseline diaphragmatic mobility at 3 months
Body Composition
Time Frame: Change from Baseline body composition at 3 months
Body composition will be evaluated through bioimpedance balance
Change from Baseline body composition at 3 months
Inflammatory markers
Time Frame: Change from Baseline inflammatory markers at 3 months
Blood concentration of Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and brain-derived neurotrophic factor (BDNF) will be assessed through blood plasma sample.
Change from Baseline inflammatory markers at 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

May 30, 2019

Study Completion (Actual)

July 30, 2019

Study Registration Dates

First Submitted

September 25, 2018

First Submitted That Met QC Criteria

September 26, 2018

First Posted (Actual)

September 28, 2018

Study Record Updates

Last Update Posted (Actual)

September 25, 2019

Last Update Submitted That Met QC Criteria

September 24, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • WBV on inflammatory biomarkers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frail Elderly Syndrome

Clinical Trials on WBV + IMT

3
Subscribe